Santhera Pharmaceuticals Holding Stock Net Income
| SPHDFDelisted Stock | USD 13.35 0.00 0.00% |
As of the 17th of February 2026, Santhera Pharmaceuticals has the Variance of 2.11, risk adjusted performance of 0.0121, and Coefficient Of Variation of 10576.3. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Santhera Pharmaceuticals, as well as the relationship between them. Please validate Santhera Pharmaceuticals standard deviation, as well as the relationship between the treynor ratio and kurtosis to decide if Santhera Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 13.35 per share. Given that Santhera Pharmaceuticals has variance of 2.11, we advise you to double-check Santhera Pharmaceuticals Holding's current market performance to make sure the company can sustain itself at a future point.
Santhera Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Santhera Pharmaceuticals' valuation are provided below:Santhera Pharmaceuticals Holding does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Santhera |
Search Suggestions
| SPH | Suburban Propane Partners | Company |
| SPHIX | Fidelity High Income | Mutual Fund |
| SPHQ | Invesco SP 500 | ETF |
| SPHYDA | SP High Yield | Index |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Santhera Pharmaceuticals Holding reported net income of (55.53 Million). This is 116.27% lower than that of the Healthcare sector and 179.27% lower than that of the Biotechnology industry. The net income for all United States stocks is 109.72% higher than that of the company.
Santhera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santhera Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santhera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics of similar companies.Santhera Pharmaceuticals is currently under evaluation in net income category among its peers.
Santhera Fundamentals
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 60.45 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (6.80) X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 469.19 X | |||
| Revenue | (1.59 M) | |||
| Gross Profit | (5.36 M) | |||
| EBITDA | (34.57 M) | |||
| Net Income | (55.53 M) | |||
| Cash And Equivalents | 21.21 M | |||
| Cash Per Share | 0.43 X | |||
| Total Debt | 25.8 M | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (37.36 M) | |||
| Earnings Per Share | (1.68) X | |||
| Number Of Employees | 39 | |||
| Beta | 0.8 | |||
| Market Capitalization | 74.18 M | |||
| Total Asset | 91.12 M | |||
| Retained Earnings | (291 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 74 M | |||
| Current Liabilities | 10 M | |||
| Z Score | -3.0 | |||
| Net Asset | 91.12 M |
About Santhera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santhera Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santhera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santhera Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Santhera Pink Sheet
If you are still planning to invest in Santhera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Santhera Pharmaceuticals' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets |